תוצאות חיפוש עבור קאפושי-סרקומה

מדובר באבן בעלת הרכב של קלציום אוקסלט מונוהידראט

חומצה אורית כן

אתה מתאר מגע מיני מזדמן לא מוגן. אין ספק שצריך להיבדק ל HIV 3 שבועות אחר כך. אם אתה שלילי הסיכוי להדבקה ב KS הוא אפסי. רק אם יש הדבקה באיידס זה עשוי לקרות.

שלום רב, בבקשה. Edwards JD, Burka JM, Bower KS, Stutzman RD, Sediq DA, Rabin JC. Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery. J Cataract Refract Surg. 2008 Sep;34(9):1538-41. doi: 10.1016/j.jcrs.2008.05.029. PMID: 18721716.

שלום רב, בבקשה. Edwards JD, Burka JM, Bower KS, Stutzman RD, Sediq DA, Rabin JC. Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery. J Cataract Refract Surg. 2008 Sep;34(9):1538-41. doi: 10.1016/j.jcrs.2008.05.029. PMID: 18721716.

אבן סידן, אבל הסיבה להיווצרותה מגוונת ומחייבת איסוף שתן בכל מקרה רצוי לשתות הרבה והלתחיל לאחר איסוף השדתן בפוטסיום ציטראט

כן הזמן סביר הרבה בריאות ..

רצוי לא לשאוף עשן ולהתרחק מהאש

ממליצה לך לעבור ברור ספציפי ( תרביות, בדיקות דם ושתן) למחלות מין ולטפל בהתאם. ד"ר עדה גרובר מומחית למחלות נשים פריון ולידה יועצת לצוואר הרחם טל. 03-6702038,9 פקס: 03-6704158

טיפול פוטודינמי יעיל מאד לטיפול BCC KS וגם בשלב הראשוני של SCC. אפשר לטפל בפעם אחת בכל הפנים. בשביל הטיפול מורחים משחה של ALA ואחרי מספר שעות מאירים עם אור בצבע אדום שמתאים להפעלת התרופה. במשך מספר דקות עד כיבוי המנורה יש עקצוץ או כאב קל.

ערב טוב, מקבל דרך מכבי. עובד בשתי מרפאות - בטירת הכרמל ובקרית מוצקין. לקביעת תור ממליץ להתקשר לזימון התורים של מכבי.

שלום רב א. על מנת להתמודד עם האדמומיות ניתן לבצע את הטיפול לסרוגין ולהוריד את התדירות לרמה שאינה מפריעה לתפקוד. ב.לא ניתן לבצע שעווה בפנים בזמן הטיפול ברטין A. ג. רטיןA יעיל לקמטוטים . השיפור לוקח חודשים רבים ויש להתאזר בסבלנות. ד. ניתן להשתמש בו ללא הפסקה מלבד בתקופת הריונות. בברכה ד"ר שלקוביץ www.derma.md

גיל שלום, נדיר מאוד. 1: Noshita N, Mashiyama S, Fukawa O, Asano S, Watanabe M, Tominaga T. Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report. Neurol Med Chir (Tokyo). 2010;50(2):161-4. PubMed PMID: 20185886. 2: Zhen L, Yufeng C, Zhenyu S, Lei X. Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J Neurooncol. 2010 May;97(3):451-7. Epub 2009 Nov 7. Review. PubMed PMID: 19898745. 3: Frank S, Kuhn SA, Brodhun M, Mueller U, Romeike B, Kosmehl H, Regenbrecht CR, Ewald C, Reichart R, Kalff R. Metastatic glioblastoma cells use common pathways via blood and lymphatic vessels. Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90. PubMed PMID: 19484696. 4: Miliaras G, Tsitsopoulos PP, Markoula S, Kyritsis A, Polyzoidis KS, Malamou-Mitsi V. Multifocal glioblastoma with remote cutaneous metastasis: a case report and review of the literature. Cen Eur Neurosurg. 2009 Feb;70(1):39-42. Epub 2009 Feb 3. PubMed PMID: 19191206. 5: Mentrikoski M, Johnson MD, Korones DN, Scott GA. Glioblastoma multiforme in skin: a report of 2 cases and review of the literature. Am J Dermatopathol. 2008 Aug;30(4):381-4. PubMed PMID: 18645311. 6: Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G. Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien). 2008 Jul;150(7):699-702; discussion 702-3. Epub 2008 Jun 12. Review. PubMed PMID: 18548193.

LINK : http://www.ncbi.nlm.nih.gov/pubmed/15170433?1ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA&linkpos=4&log$=relatedreviews&logdbfrom=pubmed וגם In vitro fertilization in two patients with Kartagener's syndrome AND infertility.Abu-Musa A, Nassar A, Usta I. Department of Obstetrics AND Gynecology, American University of Beirut Medical Center, Beirut, Lebanon. [email protected] Women with Kartagener's syndrome (KS) are at a risk for infertility because of the dyskinetic ciliary activity in the fallopian tubes. In vitro fertilization - embryo transfer (IVF-ET) is considered the treatment of choice for patients with tubal factor infertility. In the literature only 2 patients with KS were treated with IVF-ET, with only one pregnancy achieved. We report 2 patients with KS AND infertility treated successfully with IVF-ET. (c) 2007 S. Karger AG, Basel Gynecol Obstet Invest. 2008;65(1):29-31. Epub 2007 Jul 31

יש מאמר באתר baby4u.co.il המאמר האחרון הופיע החודש: Jensen A, Sharif H, Frederiksen K, Krüger Kjær S. Use of fertility drugs AND risk of ovarian cancer: Danish population based cohort study. BMJ 2009;338:b249 Objective To examine the effects of fertility drugs on overall risk of ovarian cancer using data from a large cohort of infertile women. Design Population based cohort study. Setting Danish hospitals AND private fertility clinics. Participants 54 362 women with infertility problems referred to all Danish fertility clinics during 1963-98. The median age at first evaluation of infertility was 30 years (range 16-55 years), AND the median age at the end of follow-up was 47 (range 18-81) years. Included in the analysis were 156 women with invasive epithelial ovarian cancer (cases) AND 1241 subcohort members identified in the cohort during follow-up in 2006. Main outcome measure Effect of four groups of fertility drugs (gonadotrophins, clomifene citrate, human chorionic gonadotrophin, AND gonadotrophin releasing hormone) on overall risk of ovarian cancer after adjustment for potential confounding factors. Results Analyses within cohort showed no overall increased risk of ovarian cancer after any use of gonadotrophins (rate ratio 0.83, 95% confidence interval 0.50 to 1.37), clomifene (1.14, 0.79 to 1.64), human chorionic gonadotrophin (0.89, 0.62 to 1.29), OR gonadotrophin releasing hormone (0.80, 0.42 to 1.51). Furthermore, no associations were found between all four groups of fertility drugs AND number of cycles of use, length of follow-up, OR parity. Conclusion No convincing association was found between use of fertility drugs AND risk of ovarian cancer. Use of fertility drugs AND risk of ovarian cancer: Danish population based cohort study) http://www.bmj.com/cgi/doi/10.1136/bmj.b249 (Editorial: Fertility drugs AND ovarian cancer) http://www.bmj.com/cgi/doi/10.1136/bmj.a3075 The use of fertility drugs does not increase a woman’s risk of developing ovarian cancer, finds a large study from Danish researchers published on bmj.com today. During the past three decades there has been considerable debate as to whether use of fertility drugs increases a woman’s risk of developing ovarian cancer. Previous studies have given conflicting results AND concerns remain, particularly for women who undergo several cycles of treatment OR who never succeed in becoming pregnant. So Allan Jensen AND colleagues at the Danish Cancer Society examined the effects of fertility drugs on ovarian cancer risk by using data from the largest cohort of infertile women to date. The study involved 54,362 women with infertility problems referred to all Danish fertility clinics between 1963 AND 1998. 156 of these women had ovarian cancer. After adjusting for several risk factors, the researchers assessed the effects of four groups of fertility drugs over an average period of 16 years. They found no overall increased risk for ovarian cancer after use of any fertility drug. They also found no increased risk among women who had undergone 10 OR more cycles of treatment OR among those who did not become pregnant. Although the authors did observe a statistically significant increase in risk of the most common serious type of ovarian cancer among women who had used the drug clomiphene, they stress that this was probably a chance association. Our results show no convincing association between the overall risk for ovarian cancer AND use of fertility drugs, AND are generally reassuring, say the authors. However, they do point out that, as many of the study participants have not yet reached the peak age for ovarian cancer, they will continue to monitor the risk. In a society where there is more AND more female infertility AND later age at birth of the first child, the unfavourable effects of fertility drugs should be balanced against the physical AND psychological benefits of a pregnancy made possible only by the use of these drugs, they conclude. These data are reassuring AND provide further evidence that use of fertility drugs does not increase a woman’s risk of ovarian cancer to any great extent although, small increases in risk cannot be ruled out, warns Penelope Webb of the Queensland Institute of Medical Research, in an accompanying editorial. Some women who take fertility drugs will inevitably develop ovarian cancer by chance alone, she writes, but the current evidence suggests that women who use these drugs are not increasing their risk of developing this highly fatal cancer. Published 5 February 2009, doi:10.1136/bmj.a3075 Cite this as: BMJ 2009;338:a3075 Editorials Fertility drugs AND ovarian cancer Current evidence shows no increased risk During the past two decades, considerable debate has centred around whether the use of fertility drugs increases a woman’s risk of developing ovarian cancer. Most ovarian cancers are assumed to arise from the layer of epithelial cells surrounding the ovary, AND it has been suggested that the repeated cycle of damage AND repair that occurs with ovulation may lead to DNA damage AND potentially cancer—the so called "incessant ovulation" hypothesis.1 By stimulating hyperovulation, fertility drugs might therefore increase the risk of cancer. A second hypothesis posits that increasing exposure to gonadotrophins increases the risk of ovarian cancer,2 AND because gonadotrophins are used to treat infertility, such treatment might, theoretically, put patients at risk. In the linked study (doi:10.1136/bmj.b249), Jensen AND colleagues use data from a large cohort study of infertile women to assess the effects of fertility drugs on the risk of ovarian cancer.3 Anxiety was initially fuelled by two studies suggesting that women who had taken fertility drugs had an increased risk of developing ovarian cancer.4 5 However, these studies included only 20 AND 11 women with ovarian cancer who had used fertility drugs. Subsequent studies have generally reported no association,6 but concerns remain, particularly for women who undergo 12 OR more cycles of treatment OR who never succeed in becoming pregnant. For example, a Cochrane review on the use of clomifene citrate for unexplained subfertility mentions that use for more than 12 cycles has been associated with increased risk of ovarian cancer.7 Cochrane reviews are, rightly, highly respected AND widely accessible to clinicians AND patients, yet the body of the review suggests the statement about ovarian cancer risk is based solely on the results of the early studies.4 5 So should women seeking treatment for infertility be worried that fertility drugs might increase their risk of ovarian cancer? More than 10 cohort studies AND a similar number of case-control studies have attempted to answer this question. Most have been limited by small sample sizes—only three studies have included more than 25 women with ovarian cancer who have used fertility drugs.8 9 10 Furthermore, infertility itself is a risk factor for ovarian cancer,9 but many studies have been unable to separate the potential effects of the use of fertility drugs on the risk of ovarian cancer from the effects of the underlying infertility; others could not control for potentially important confounding factors such as parity AND use of oral contraceptives. Jensen AND colleagues’ study included 54 362 women with infertility problems referred to Danish fertility clinics from 1963 to 1998.3 It found that use of four groups of fertility drugs (gonadotrophins, clomifenes, human chorionic gonadotrophin, AND gonadotrophin releasing hormone) was not associated with an overall increase in the risk of ovarian cancer. They also found no suggestion that risk was increased in women who had undergone 10 OR more cycles of treatment OR in those who remained nulliparous. Although the authors did see a significantly increased risk of the most common serous subtype of ovarian cancer in women who had used clomifene, this was just one of 20 separate comparisons in their subgroup analyses AND was probably a chance association. This study is important because it included 156 women with ovarian cancer, more than three times as many as any previous cohort study, AND it compared infertile women who had used fertility drugs with infertile women who had not used fertility drugs. Although information on parity AND use of oral contraceptives was unavailable for many women, analyses in the subgroup of women with this information suggested that adjusting for these variables would have had little effect on the results. However, although the study was much larger than previous investigations, it still could not exclude the possibility of a small increase in the risk of ovarian cancer in users of fertility drugs—the rate ratio for use of any fertility drug was 1.03, but the upper bound of the 95% confidence interval was 1.47.3 Larger numbers of women will need to be studied to answer this question, AND these will come with further follow-up of the cohort as they enter the age range where ovarian cancer is most common. These data are reassuring AND provide further evidence that fertility drugs do not increase a woman’s risk of ovarian cancer to any great extent, although small increases in risk cannot be ruled out. Given the increasing numbers of women seeking fertility treatment,11 this is important information for clinicians AND their patients, AND in a world where women increasingly turn to the internet for health information, clinicians should take time to discuss this matter so that women are properly informed. Some women who take fertility drugs will inevitably develop ovarian cancer by chance alone, but current evidence suggests that women who use these drugs do not have an increased risk of developing ovarian cancer. Cite this as: BMJ 2009;338:a3075 Penelope M Webb, senior research fellow 1 Queensland Institute of Medical Research, Royal Brisbane Hospital, Brisbane, QLD 4029, Australia [email protected] Research, doi:10.1136/bmj.b249 ________________________________________ Competing interests: None declared. Provenance AND peer review: Commissioned; not externally peer reviewed. References 1. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? Lancet 1971;2:163.[CrossRef][ISI][Medline] 2. Cramer DW, Welch WR. Determinants of ovarian cancer risk II: inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.[ISI][Medline] 3. Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs AND subsequent risk for ovarian cancer: Danish population based cohort study. BMJ 2009;338:b249.[Abstract/Free Full Text] 4. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.[Abstract/Free Full Text] 5. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-6.[Abstract/Free Full Text] 6. Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ. Ovulation induction AND cancer risk. Fertil Steril 2005;83:261-74.[CrossRef][ISI][Medline] 7. Hughes E, Brown J, Collins J, Vanderkerckhove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000;(1):CD000057. 8. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004;103:1194-203.[CrossRef][ISI][Medline] 9. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, AND invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-12.[CrossRef][ISI][Medline] 10. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, AND ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-24.[Abstract/Free Full Text] 11. Human Fertilisation AND Embryology Authority. Facts AND figures 2006—fertility problems AND treatment 2008., www.hfea.gov.uk/docs/2008-10-08_Facts_and_Figures_2006_-_fertility_problems_and_treatment.pdf.

קפושי הם נגעים כחולים בעור שבולטים. בדרך כלל לוקח הרבה זמן להופעתם לאחר החשיפה. במידה ויש לך נגע כזה כדאי להיבדק.

גידול ממאיר של סרקומה ע"ש קפוסי נגרם על ידי וירוס הרפס מספר 8. דרך ההדבקה אינה ברורה לגמרי וכן לא הגורמים להתפרצות המחלה. ההערכה היא שבארה"ב למשל שיעור הנשים של הוירוס הנע מ 3.5% ועד ל 25% ובאפריקה כ 50%. רק מעטים מכל אלו אכן חולים במחלה.

גם במגע מיני ובחיכון בעור.

שלום רוני, כנראה שלא. הרבה בריאות אפי

יוסי לא ברור לי באיזה תוסף אתה רוצה לשתמש כי aml זה הקיצור של שם הלאוקמיה (Acute Myeloid Leukemia). המלצות שלי לטיפול בלאוקמיה: 2 צמחי מרפא fevefew AND Boscari ד"ר יוסף ברנר

My answer ıs ın Englısh as I am not ın Israel now. Touch therapy ıs a part of reıkı healıng technıks. You can learn more ın web sıtes dealıng wıth ıt lıke www..touchtherapyınstıtue.com I am not sure ıf there are research evıdence about the ınfluence of touch therapy on the ımmune system Joseph Brenner M.d

שלום שואל, KS מתבטאת בפריחה אופיינית על העור או על הריריות שמתפתחת באיטיות (יחסית). ראה למשל את התמונות בקישורית הבאה: http://images.google.com/images?hl=en&q=kaposi%20sarcoma&btnG=Google+Search&sa=N&tab=wi הרבה בריאות אפי

שלום מישהו, כן. הרבה בריאות אפי

תיאור הסימנים הקליניים של הכלבה מצדיק בדיקה של רופא וטרינר ואולי מעורבות נוירולוג מומחה. לתת חחות דעת ללא בדיקת הכלבה אינו מקצועי ואינו אחראי. חג שמח!